Last checked at 13 Aug 2018 10:48
PDMR Dealings / Market Share Sale
Oxford, UK - 13 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Kyriacos Mitrophanous, Chief Scientific Officer, exercised 13,395 options at 50p ("Ordinary Shares") in the Company on 09 August 2018 and sold all the resulting shares at 904.416p. Following this transaction Kyriacos Mitrophanous holds 164,332 options in the Company.
375 options were exercised at 101.5p and all the resulting shares were sold at 904.416p by Kyriacos Mitrophanous wife (Pippa Radcliffe) and are therefore considered a beneficial holding of Kyriacos Mitrophanous.
The issued share capital of the Company is 65,752,788 ordinary shares of 50 pence each.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Kyriacos Mitrophanous
| |
2. | Reason for the notification
| ||
a. | Position/status | Chief Scientific Officer
| |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford BioMedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Ordinary Shares of 50p each
ISIN: GB00BDFBVT43
| |
b. | Nature of the transaction | Exercise of Options
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
|
| £0.50 | 13,395 |
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
13,395
£0.50 £6,697.5
| |
f. | Date of the transaction | 2018-08-13
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Kyriacos Mitrophanous
| |
2. | Reason for the notification
| ||
a. | Position/status | Chief Scientific Officer
| |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford BioMedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Ordinary Shares of 50p each
ISIN: GB00BDFBVT43
| |
b. | Nature of the transaction | Disposal
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
|
| £9.04416 | 13,395 |
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
13,395
£9.04416 £121,146.52
| |
f. | Date of the transaction | 2018-08-13
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Pippa Radcliffe
| |
2. | Reason for the notification
| ||
a. | Position/status | Person closely associated with Kyriacos Mitrophanous, Chief Scientific Officer
| |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford BioMedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Ordinary shares of 50p each
ISIN: GB00BDFBVT43
| |
b. | Nature of the transaction | Purchase of ordinary shares
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
£1.015 | 375 | ||
|
| ||
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
375
£101.5 £380.63
| |
f. | Date of the transaction | 2018-08-13
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Pippa Radcliffe
| |
2. | Reason for the notification
| ||
a. | Position/status | Person closely associated with Kyriacos Mitrophanous, Chief Scientific Officer
| |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford BioMedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Disposal
| |
b. | Nature of the transaction | Purchase of ordinary shares
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
£9.04416 | 375 | ||
|
| ||
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
375
£9.04416 £3,391.5
| |
f. | Date of the transaction | 2018-08-13
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
|
Tel: +44 (0)20 3709 5700 |
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.